The influence of extracellular matrix on the generation of vascularized, engineered, transplantable tissue.
In a recently described model for tissue engineering, an arteriovenous loop comprising the femoral artery and vein with interposed vein graft is fabricated in the groin of an adult male rat, placed inside a polycarbonate chamber, and incubated subcutaneously. New vascularized granulation tissue will generate on this loop for up to 12 weeks. In the study described in this paper three different extracellular matrices were investigated for their ability to accelerate the amount of tissue generated compared with a no-matrix control. Poly-D,L-lactic-co-glycolic acid (PLGA) produced the maximal weight of new tissue and vascularization and this peaked at two weeks, but regressed by four weeks. Matrigel was next best. It peaked at four weeks but by eight weeks it also had regressed. Fibrin (20 and 80 mg/ml), by contrast, did not integrate with the generating vascularized tissue and produced less weight and volume of tissue than controls without matrix. The limiting factors to growth appear to be the chamber size and the capacity of the neotissue to integrate with the matrix. Once the sides of the chamber are reached or tissue fails to integrate, encapsulation and regression follow. The intrinsic position of the blood supply within the neotissue has many advantages for tissue and organ engineering, such as ability to seed the construct with stem cells and microsurgically transfer new tissue to another site within the individual. In conclusion, this study has found that PLGA and Matrigel are the best matrices for the rapid growth of new vascularized tissue suitable for replantation or transplantation.
Cassell
O C
OC
Bernard O'Brien Institute of Microsurgery, University of Melbourne, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
Morrison
W A
WA
Messina
A
A
Penington
A J
AJ
Thompson
E W
EW
Stevens
G W
GW
Perera
J M
JM
Kleinman
H K
HK
Hurley
J V
JV
Romeo
R
R
Knight
K R
KR
D000818:Animals; D001808:Blood Vessels / Q000254:growth & development*; D003094:Collagen; D004338:Drug Combinations; D005109:Extracellular Matrix / Q000502:physiology*; D007150:Immunohistochemistry; D019344:Lactic Acid; D007797:Laminin; D008297:Male; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011509:Proteoglycans; D051381:Rats; D017207:Rats, Sprague-Dawley; D023822:Tissue Engineering
D004338:Drug Combinations; D007797:Laminin; D011108:Polymers; D011509:Proteoglycans; C059485:matrigel; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D003094:Collagen